MedPath

Aspirin

Generic Name
Aspirin
Brand Names
Aggrenox, Alka-seltzer, Alka-seltzer Fruit Chews, Anacin, Arthriten Inflammatory Pain, Ascomp, Aspi-cor, Aspir-low, Bayer Aspirin, Bayer Womens, Bc Arthritis, Bc Original Formula, Bufferin, Duoplavin, Durlaza, Ecotrin, Ecpirin, Endodan Reformulated May 2009, Equagesic, Exaprin, Excedrin, Excedrin PM Triple Action, Fasprin, Fiorinal, Goody's Body Pain, Goody's Extra Strength, Goody's PM, Miniprin, Norgesic, Norgesic Forte, Orphengesic, Pamprin Max Formula, Robaxisal, ST. Joseph Aspirin, Stanback Headache Powder Reformulated Jan 2011, Trianal, Trianal C, Vanquish, Vazalore, Yosprala
Drug Type
Small Molecule
Chemical Formula
C9H8O4
CAS Number
50-78-2
Unique Ingredient Identifier
R16CO5Y76E
Background

Also known as Aspirin, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial infarction (MI) .

Interestingly, the results of various studies have demonstrated that long-term use of acetylsalicylic acid may decrease the risk of various cancers, including colorectal, esophageal, breast, lung, prostate, liver and skin cancer . Aspirin is classified as a non-selective cyclooxygenase (COX) inhibitor and is available in many doses and forms, including chewable tablets, suppositories, extended release formulations, and others .

Acetylsalicylic acid is a very common cause of accidental poisoning in young children. It should be kept out of reach from young children, toddlers, and infants .

Indication

Pain, fever, and inflammation

Acetylsalicylic acid (ASA), in the regular tablet form (immediate-release), is indicated to relieve pain, fever, and inflammation associated with many conditions, including the flu, the common cold, neck and back pain, dysmenorrhea, headache, tooth pain, sprains, fractures, myositis, neuralgia, synovitis, arthritis, bursitis, burns, and various injuries. It is also used for symptomatic pain relief after surgical and dental procedures .

The extra strength formulation of acetylsalicylic acid is also indicated for the management migraine pain with photophobia (sensitivity to light) and phonophobia (sensitivity to sound).

Other indications

ASA is also indicated for various other purposes, due to its ability to inhibit platelet aggregation. These include:

Reducing the risk of cardiovascular death in suspected cases of myocardial infarction (MI) .

Reducing the risk of a first non-fatal myocardial infarction in patients, and for reducing the risk of morbidity and mortality in cases of unstable angina and in those who have had a prior myocardial infarction .

For reducing the risk of transient ischemic attacks (TIA) and to prevent atherothrombotic cerebral infarction (in conjunction with other treatments) .

For the prevention of thromboembolism after hip replacement surgery .

For decreasing platelet to platelet adhesion following carotid endarterectomy, aiding in the prevention of transient ischemic attacks (TIA) .

Used for patients undergoing hemodialysis with a silicone rubber arteriovenous cannula inserted to prevent thrombosis at the insertion site .

Important note regarding use of the extended-release formulation

In the setting of acute myocardial infarction, or before percutaneous interventions, the extended-release form of acetylsalicylic acid should not be used. Use immediate-release formulations in scenarios requiring rapid onset of action . The extended-release form is taken to decrease the incidence of mortality and myocardial infarction (MI) for individuals diagnosed with chronic coronary artery disease (CAD), including patients with previous myocardial infarction (MI) or unstable angina or with chronic stable angina. Additionally, the extended-release form is used to decrease the risk of death and recurrent episodes of stroke in patients with a history of stroke or TIA .

Associated Conditions
Acute Coronary Syndrome (ACS), Anxiety, Atherothrombotic cerebral infarction, Cardiovascular Disease (CVD), Cardiovascular Events, Cardiovascular Mortality, Colorectal Adenomas, Colorectal Cancer, Common Cold, Coronary artery reocclusion, Death, Dyspeptic signs and symptoms, Fever, Flu caused by Influenza, Headache, Heterozygous Familial Hypercholesterolemia (HeFH), Inflammation, Juvenile Idiopathic Arthritis (JIA), Major Adverse Cardiovascular and Cerebrovascular Events (MACCE), Menstrual Pain, Migraine, Morbidity, Mucocutaneous Lymph Node Syndrome, Muscle Contraction, Myalgia, Myocardial Infarction, Myocardial Infarction (MI), first occurrence, Neuropathic Pain, Pain, Pain caused by Common Cold, Pain caused by Rheumatism, Pericarditis, Polycythemia Vera (PV), Pre-Eclampsia, Rheumatism, Rheumatoid Arthritis, Rhino Sinusitis, Severe Pain, Spondyloarthropathies, Stroke, Systemic Lupus Erythematosus, Tension Headache, Thromboembolism, Thrombosis, Toothache, Transient Ischemic Attack, Vascular Death, Venous Thromboembolism, Acute Inflammation, Articular inflammation, Atherothrombotic events, Death caused by Myocardial Infarction, Fever or influenza-like illness, Moderate Pain, Recurrent Ischemic Stroke
Associated Therapies
Anti-platelet Therapy, Hemodialysis Treatment, Secondary Prevention

Aspirin and Zileuton and Biomarker Expression in Nasal Tissue of Current Smokers

Phase 2
Completed
Conditions
Tobacco Use Disorder
Interventions
Drug: Aspirin
Other: Laboratory Biomarker Analysis
Other: Placebo Administration
Drug: Zileuton
First Posted Date
2015-01-28
Last Posted Date
2022-06-02
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
63
Registration Number
NCT02348203
Locations
🇺🇸

Banner University Medical Center - Tucson, Tucson, Arizona, United States

🇺🇸

Boston University School of Medicine, Boston, Massachusetts, United States

Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986141 in Healthy Subjects

Phase 1
Completed
Conditions
Thrombosis
Interventions
First Posted Date
2015-01-19
Last Posted Date
2017-03-31
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
148
Registration Number
NCT02341638
Locations
🇺🇸

West Coast Clinical Trials, Llc, Cypress, California, United States

🇺🇸

Ppd Development, Lp, Austin, Texas, United States

Aspirin for Venous Ulcers: Randomised Trial (AVURT)

Phase 2
Terminated
Conditions
Venous Leg Ulcer
Interventions
Drug: Placebo (for Aspirin)
Drug: Aspirin
First Posted Date
2015-01-07
Last Posted Date
2017-06-27
Lead Sponsor
St George's, University of London
Target Recruit Count
26
Registration Number
NCT02333123
Locations
🇬🇧

St George's University Hospitals NHS Foundation Trust, Tooting, London, United Kingdom

🇬🇧

Hull & East Yorkshire Hospital NHS Trust, Cottingham, Castle hill hosp, United Kingdom

🇬🇧

Brighton General Hosp, Brighton, Sussex, United Kingdom

and more 2 locations

Low-dose Aspirin Therapy for Esophageal Cancer

Phase 3
Withdrawn
Conditions
Esophageal Cancer
Interventions
First Posted Date
2014-12-29
Last Posted Date
2021-04-27
Lead Sponsor
Zhejiang University
Registration Number
NCT02326779

Comparative Efficacy of Ticagrelor Versus Aspirin on Blood Viscosity in Peripheral Artery Disease Patients With Type 2 Diabetes

Phase 3
Completed
Conditions
Peripheral Artery Disease
Type 2 Diabetes
Interventions
First Posted Date
2014-12-25
Last Posted Date
2022-03-21
Lead Sponsor
Icahn School of Medicine at Mount Sinai
Target Recruit Count
70
Registration Number
NCT02325466
Locations
🇺🇸

Icahn School of Medicine at Mount Sinai, New York, New York, United States

Combined Multi-marker Screening and Treatment With Aspirin for Pre-eclampsia Prevention

Phase 3
Completed
Conditions
Preeclampsia
Interventions
Drug: Placebo
Drug: Aspirin
First Posted Date
2014-11-26
Last Posted Date
2016-11-09
Lead Sponsor
Rabin Medical Center
Target Recruit Count
2
Registration Number
NCT02301780
Locations
🇮🇱

Rabin Medical Center, Petach-Tikva, Israel

A Trial of Aspirin on Recurrence and Survival in Colon Cancer Patients

Phase 3
Active, not recruiting
Conditions
Adjuvant Therapy
Colon Cancer
Interventions
Drug: Acetylsalicylic acid
Drug: Placebo Acetylsalicylic acid
First Posted Date
2014-11-25
Last Posted Date
2024-03-18
Lead Sponsor
Leiden University
Target Recruit Count
770
Registration Number
NCT02301286
Locations
🇳🇱

Ziekenhuis St. Jansdal, Harderwijk, Netherlands

🇳🇱

Antonius Ziekenhuis, Sneek, Netherlands

🇳🇱

Deventer Ziekenhuis, Deventer, Netherlands

and more 29 locations

Dabigatran Following Transient Ischemic Attack and Minor Stroke

Phase 2
Completed
Conditions
Transient Ischemic Attack
Minor Ischemic Stroke
Interventions
First Posted Date
2014-11-20
Last Posted Date
2019-01-30
Lead Sponsor
University of Alberta
Target Recruit Count
300
Registration Number
NCT02295826
Locations
🇨🇦

Hamilton Health Sciences, Hamilton, Ontario, Canada

🇨🇦

University of Calgary, Calgary, Alberta, Canada

🇨🇦

University of Alberta, Edmonton, Alberta, Canada

and more 3 locations

Study Design of 'Influence of Sarpogrelate in Patients With Renal Impairment or Diabetes Mellitus' Study

Phase 3
Completed
Conditions
Diabetes Mellitus
Renal Insufficiency, Chronic
Coronary Artery Disease
Interventions
Drug: Sarpogrelate
Drug: Aspirin
Drug: Clopidogrel
Drug: Placebo (for Sarpogrelate)
First Posted Date
2014-11-19
Last Posted Date
2014-11-25
Lead Sponsor
Seoul National University Bundang Hospital
Target Recruit Count
220
Registration Number
NCT02294643
Locations
🇰🇷

Seoul National University Bundang Hospital, Seongnam, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath